



November 7, 2019

✓ **The BSE Limited,**
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.

Enclosed is a Press Note wherein American Association of Indian Pharmaceutical Scientists (AAiPS) in collaboration with the Indian Pharmaceutical Association, announced Dr. Umesh Gupta, Assistant Professor, Central University of Rajasthan, as the recipient of the Dr. Desh Bandhu Gupta AAiPS Award at the AAiPS Annual Meeting 2019 in San Antonio, Texas (U.S.).

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For **LUPIN LIMITED**

For 
R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)



Encl.: a/a

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com

Dr. Desh Bandhu Gupta AAiPS Award 2019 Conferred on Dr. Umesh Gupta

Mumbai, San Antonio, November 7, 2019: American Association of Indian Pharmaceutical Scientists (AAiPS) in collaboration with the Indian Pharmaceutical Association (IPA), announced Dr. Umesh Gupta, Assistant Professor, Central University of Rajasthan, as the recipient of the Dr. Desh Bandhu Gupta AAiPS Award at the AAiPS Annual Meeting 2019 in San Antonio, Texas (U.S.).

The Dr. Desh Bandhu Gupta AAiPS Award, formerly known as the AAiPS Distinguished Young Educator and Researcher Award, recognizes individuals who have made significant and consistent contribution to teaching and research in Pharmaceutical Sciences and Technology at any recognized academic institution in India.

On the occasion, **Dr. Xian-Ming Zeng, EVP, Head of Inhalation & Complex Injectables R&D, Lupin Limited** said "Dr. Desh Bandhu Gupta (DBG), the founder of Lupin Limited, helped the Indian pharmaceutical industry find its place on the global map. This was catalyzed by DBG's acute focus on pharmaceutical research and academics. The Dr. Desh Bandhu Gupta AAiPS Award 2019 felicitates faculty members from the field of training and pharmaceutical research who demonstrate unwavering commitment and tireless efforts to constantly contribute to this field. We congratulate Dr. Umesh Gupta for receiving this award."

A three-member judging panel, comprising Dr. Sampat Singhvi, Dr. Punit Marathe and Mr. Mike Yelvigi, evaluated numerous submissions and selected Dr. Umesh Gupta to receive this award for his significant and consistent contributions toward teaching and research in the field of Pharmaceutical Sciences and Technology.

On receiving the award, Dr. Umesh Gupta said, "I am delighted and honored to receive the prestigious Dr. Desh Bandhu Gupta AAiPS Award. This award recognizes my work and efforts toward pharmaceutical R&D in India. Such recognition boosts the morale of the entire pharmaceuticals researchers' community, further amplifying their focus and commitment and opening new doors of opportunity."

About AAiPS:

AAiPS is over 30 year old non-profit organization reflecting the dedicated service of the Indian pharmaceutical community in the U.S.

AAiPS serves as a platform for all Indian Scientists to network through its regional and annual meetings and the two chapters in New Jersey and Washington DC. With this strong base, AAiPS is committed to serve the professional pharmaceutical community effectively and enthusiastically for years to come.

Visit <https://www.aaips.org/> for more information.

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biosimilar products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8th largest generics pharmaceutical company by revenues (June 30, 2019, Bloomberg LTM). The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT September 2019); 3rd largest Indian pharmaceutical company by global revenues (June 30, 2019, Bloomberg LTM); 6th largest company in the Indian Pharmaceutical Market and 5th largest generic pharmaceutical player in Japan (IQVIA MAT September 2019).

Press Note



For the financial year ended March 31, 2019, Lupin's Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter at – [www.twitter.com/lupinglobal](https://twitter.com/lupinglobal)

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact-

Arvind Bothra

Head – Investor Relations and M&A / Corporate Communications

Email: arvindbothra@lupin.com

Ph: +91-22-66408237